Amicus Therapeutics, Inc. FOLD was a big mover last session, as the company saw its shares rise nearly 9% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This continues the recent uptrend for the company—as the stock is now up 21.9% in the past one-month time frame.
The company has seen one negative estimate revision in the past few months, while its Zacks Consensus Estimate for the current quarter has also moved lower over the past few months, suggesting there may be trouble down the road. So make sure to keep an eye on this stock going forward, to see if this recent move higher can last.
Amicus Therapeutics currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.
Amicus Therapeutics, Inc. Price
Amicus Therapeutics, Inc. price | Amicus Therapeutics, Inc. Quote
A better-ranked stock in the Medical – Biomedical and Genetics industry is Akcea Therapeutics, Inc. AKCA, which currently carries a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Zacks Top 10 Stocks for 2020
In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-hold tickers for the entirety of 2020?
Last year's 2019 Zacks Top 10 Stocks portfolio returned gains as high as +102.7%. Now a brand-new portfolio has been handpicked from over 4,000 companies covered by the Zacks Rank. Don’t miss your chance to get in on these long-term buys.
Access Zacks Top 10 Stocks for 2020 today >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Amicus Therapeutics, Inc. (FOLD) : Free Stock Analysis Report
Akcea Therapeutics, Inc. (AKCA) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research